ArticleVirology journal2024
Mycoplasma pneumoniae infection outbreak in Guangzhou, China after COVID-19 pandemic.
Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- A machine learning-based early in-hospital risk stratification model for severe mycoplasma pneumoniae pneumonia in children.Translational pediatrics · 2026Article
- Post-pandemic surge ofJournal of clinical microbiology · 2026Article
- Changes in Epidemiological Characteristics in Children withJournal of clinical medicine · 2026Article
- Article
- Antimicrobial Susceptibility and Distribution Characteristics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Risk factors and clinical characteristics of fulminant Mycoplasma pneumoniae pneumonia in children: a retrospective case‒control study.BMC infectious diseases · 2026Article
- Article
- The expression and clinical value ofTranslational pediatrics · 2026Article
- In the shadow of COVID-19: changes in the seroprevalence of pediatric Mycoplasma pneumoniae.BMC infectious diseases · 2026Article
- Macrolide Resistance and Multilocus Sequence Typing Genotype Analysis ofPublic health weekly report · 2026Article
- Depressive and anxiety symptom trajectories in psychiatric inpatients with nosocomial infection: a retrospective study from China.Frontiers in psychiatry · 2026Article
- Pathogen Profile of Pediatric Community-Acquired Pneumonia in Wuhan, 2023: A BALF-Based Study.Canadian respiratory journal · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Targeted Next-Generation Sequencing Reveals Distinct Pathogen Profiles in Community-Acquired Pneumonia Across Age and Disease Severity.Infection and drug resistance · 2026Article
- Clinical characteristics of hospitalized children with mycoplasma pneumoniae pneumonia in Chinese tertiary hospitals during the 2023-2024 post-pandemic period.Frontiers in cellular and infection microbiology · 2026Article
- Epidemiological trends, antimicrobial resistance, and genetic mutations ofOpen medicine (Warsaw, Poland) · 2026Article
- Epidemiology and co-infection networks of pediatric respiratory pathogens in eastern China after COVID-19 restriction relaxation: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Characterizing the epidemiology ofEmerging microbes & infections · 2025Article
- A one-pot, visual, multiplex microfluidic digital PCR chip for simultaneous point-of-care detection, genotyping, and macrolide resistance assessment of Mycoplasma pneumoniae.Mikrochimica acta · 2025Article
- Mycoplasma pneumoniae in hospitalised children in the post-COVID era: clinical outcomes from a Turkish multicenter cohort.European journal of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundsMycoplasma pneumoniae (M. pneumoniae) is a common pathogen causing respiratory diseases in children. This study aimed to characterize epidemiological and disease severity shifts of M. pneumoniae: infections in Guangzhou, China during and after the coronavirus disease 2019 (COVID-19) pandemic.
methodsThroat swab samples were obtained from 5405 hospitalized patients with symptoms of acute respiratory infections to detect M. pneumoniae. Differences in epidemiological and clinical characteristics of M. pneumoniae: infections were investigated during 2020-2022 and after COVID-19 pandemic (2023).
resultsM. pneumoniae were detected in 849 (15.6%, 849/5405) patients. The highest annual positive rate was 29.4% (754/2570) in 2023, followed by 5.3% (72/1367) in 2022, 1.2% (12/1015) in 2021, and 2.0% (11/553) in 2020, with significantly increasing annual prevalence from 2020 to 2023. M. pneumoniae incidence peaked between July and December post-COVID-19 pandemic in 2023, with the highest monthly positive rate (56.4%, 165/293). Clinical characteristics and outcomes of patients with M. pneumoniae did not vary between periods during and after COVID-19 pandemic except that patients with M. pneumoniae post-COVID-19 pandemic were more likely to develop fever. Patients with severe M. pneumoniae pneumonia (SMPP) were more likely to develop respiratory complications, myocardial damage, and gastrointestinal dysfunction than those with non-SMPP. Patients with SMPP had lower lymphocytes, CD3
conclusionOutbreaks of M. pneumoniae: occurred in Guangzhou, China in 2023 upon Non-pharmaceutical interventions easing. Despite the increasing incidence of M. pneumoniae, the disease severity remained similar during and after the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.